Finally, a retrospective study comparing cyclophosphamide treatment vs. RTX in ATA-positive dcSSc patients with interstitial lung disease showed a better improvement in forced vital capacity, diffusing capacity of the lung carbon monoxide, and mean Rodnan skin score in the RTX group (57). The gene discussed is ATM; the disease is interstitial lung disease.